<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 37-year-old Japanese man with <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) developed <z:hpo ids='HP_0003473'>myasthenia</z:hpo> gravis 29 months after bone marrow transplantation (BMT) from an HLA one locus-mismatched brother </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0003701'>Proximal muscle weakness</z:hpo> and <z:hpo ids='HP_0001488'>bilateral ptosis</z:hpo> occurred along with the exacerbation of <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD shortly after sudden cessation of <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> (CYA) and <z:chebi fb="2" ids="8378">prednisolone</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>The diagnosis of <z:hpo ids='HP_0003473'>myasthenia</z:hpo> gravis was made based on clinical symptoms and elevation of an anti-<z:chebi fb="9" ids="15355">acetylcholine</z:chebi> receptor antibody titer and <z:hpo ids='HP_0000001'>all</z:hpo> symptoms related to <z:hpo ids='HP_0003473'>myasthenia</z:hpo> gravis promptly diminished with the start of treatment for <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD </plain></SENT>
<SENT sid="3" pm="."><plain>In most previously reported cases, the underlying disease was <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (6 of 7 cases) and donors were of the opposite sex (6 of 7 cases) </plain></SENT>
<SENT sid="4" pm="."><plain>The haplotypes HLA B7 (3 of 5 cases), B35 (3 of 5 cases), and DR2 (3 of 3 cases) were common </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> cases suffered from <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD </plain></SENT>
<SENT sid="6" pm="."><plain>The present case had only <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD and HLA B7 as a background for <z:hpo ids='HP_0003473'>myasthenia</z:hpo> gravis after BMT </plain></SENT>
<SENT sid="7" pm="."><plain>The abrupt cessation of immunosuppressive therapy may also be related to the development of <z:hpo ids='HP_0003473'>myasthenia</z:hpo> gravis after BMT </plain></SENT>
</text></document>